Mass Spectrometry as a Clinical Integrative Tool to Evaluate Hepatocellular Carcinoma: Moving to the Mainstream

Página do item simplificado
dc.contributor.authorMartins A.M.A.
dc.contributor.authorGarcia J.H.P.
dc.contributor.authorEberlin M.N.
dc.date.accessioned2024-03-12T23:55:06Z
dc.date.available2024-03-12T23:55:06Z
dc.date.issued2019
dc.description.abstract© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.Introduction: Since the pioneering work of J. J. Thomson on magnetic deflection of charged particles, mass spectrometry (MS) has become the most progressive clinical tool by continuously providing new applications in medical research. In hepatocellular carcinoma (HCC), MS can be used from surveillance in early stages of the disease to constant evaluation of effective treatments. Areas covered: This Special Report highlights the groundbreaking possibilities of mass spectrometry clinical application in the mainstream to evaluate HCC development and progression. Expert opinon: MS has been employed to understand a myriad of liver diseases, such as the identification of early biomarkers in cirrhosis and HVB and HVC, as well as metabolic alterations of lipidic imbalance in HCC due to fatty liver disease. In an integrative point-of-view, researchers worldwide are looking for molecular signatures that may represent more faithfully the complex scenario of the onset and progression of HCC. Following the steps of MELD score (Model of End-stage Liver Disease), which evaluates biochemical dysfunction of end-stage liver diseases, the necessity to use innovative attempts to pursue a molecular-MEaLD (mMEaLD–molecular Model for Early Liver Disease), shifting MS to the upstream and from the lab facilities into the mainstream, inside the surgery room.
dc.description.firstpage821
dc.description.issuenumber9
dc.description.lastpage825
dc.description.volume13
dc.identifier.doi10.1080/17474124.2019.1651643
dc.identifier.issn1747-4132
dc.identifier.urihttps://dspace.mackenzie.br/handle/10899/35372
dc.relation.ispartofExpert Review of Gastroenterology and Hepatology
dc.rightsAcesso Restrito
dc.subject.otherlanguagecancer
dc.subject.otherlanguagehepatocellular carcinoma
dc.subject.otherlanguageliver
dc.subject.otherlanguageMass spectrometry
dc.subject.otherlanguagemMEaLD
dc.titleMass Spectrometry as a Clinical Integrative Tool to Evaluate Hepatocellular Carcinoma: Moving to the Mainstream
dc.typeArtigo
local.scopus.citations1
local.scopus.eid2-s2.0-85070806434
local.scopus.subjectCarcinoma, Hepatocellular
local.scopus.subjectHumans
local.scopus.subjectLiver Neoplasms
local.scopus.subjectMass Spectrometry
local.scopus.updated2024-05-01
local.scopus.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85070806434&origin=inward
Arquivos
Coleções
Artigos de periódico